Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 14,141 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 3 Interventional

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

NCT01854567
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions
Infusion of one MPC expanded cord unit and one unexpanded cord unit, Infusion of two unexpanded cord blood units.
Biological
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
Up to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Miami, Florida • Tampa, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Nov 8, 2026, 5:16 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Klotho and Follistatin Gene Therapy

NCT07285629
View directory record Official record
Conditions
Healthy Adults
Interventions
Follistatin and klotho gene therapy
Genetic
Lead sponsor
Minicircle
Industry
Eligibility
50 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 8, 2026, 5:16 PM EST
Recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD1163, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Glendale, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 8, 2026, 5:16 PM EST
Active, not recruiting Phase 2 Interventional

Clinical Trial on Agitation in Alzheimer's Dementia

NCT05543681
View directory record Official record
Conditions
Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Interventions
IGC-AD1-Active, IGC-AD1-Placebo
Drug
Lead sponsor
IGC Pharma, LLC
Industry
Eligibility
60 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 4 Interventional Results available

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

NCT00734630
View directory record Official record
Conditions
Hypertension
Interventions
nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
75
States / cities
Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Nov 8, 2026, 5:16 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Riliprubart, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Homewood, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 2 Interventional Results available

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

NCT00950807
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo, GSK573179
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 2 Interventional

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

NCT00116129
View directory record Official record
Conditions
Fibromyalgia
Interventions
Ibutamoren Mesylate (MK-0677)
Drug
Lead sponsor
Bennett, Robert, M.D.
Individual
Eligibility
30 Years to 65 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 3 Interventional Results available

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

NCT02452931
View directory record Official record
Conditions
Precocious Puberty, Central
Interventions
Leuprolide Acetate 45 mg
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
2 Years to 9 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
San Diego, California • Hollywood, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 2 Interventional Results available

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

NCT01436045
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
65 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

NCT02235272
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Nov 8, 2026, 5:16 PM EST
Terminated Phase 2 Interventional Results available

Dysport in Vulvodynia Phase II Study

NCT03598777
View directory record Official record
Conditions
Vulvodynia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Miami, Florida • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Nov 8, 2026, 5:16 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Adaptation and Pilot Testing of a Lung Cancer Screening Decision Aid for Patients From a Safety-Net Healthcare System

NCT07382557
View directory record Official record
Conditions
Lung Cancer
Interventions
Surveys, Focus groups, Cognitive Interviews, Lung cancer screening decision aid video, Colon cancer screening video
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years to 80 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

NCT02698657
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ASP5094, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Nov 8, 2026, 5:16 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457
View directory record Official record
Conditions
Episodic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

NCT02709928
View directory record Official record
Conditions
Healthy Adults, Elderly Subjects
Interventions
TD-0714, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Nov 8, 2026, 5:16 PM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

NCT01479465
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 2 Interventional Results available

BOTOX® for the Treatment of Platysma Prominence

NCT03915067
View directory record Official record
Conditions
Platysma Prominence
Interventions
BOTOX® purified neurotoxin complex, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Coral Gables, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Nov 8, 2026, 5:16 PM EST
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
Drug · Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 2 Interventional

A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)

NCT01793441
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Placebo, RG7314
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
56
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Nov 8, 2026, 5:16 PM EST
Completed Phase 2 Interventional Results available

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00498602
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
27
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Nov 8, 2026, 5:16 PM EST
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

NCT05948553
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 8, 2026, 5:16 PM EST
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

NCT06856577
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 8, 2026, 5:16 PM EST